Compare Globus Medical Inc. Class A Common Stock (GMED) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs McDonald's Corp — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while McDonald's Corp trades at $240.31 (market cap $166.87B). The key difference: McDonald's Corp is far larger — about 16.3× Globus Medical Inc. Class A Common Stock's market cap, and McDonald's Corp pays a 3.27% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and McDonald's Corp for 165 Days on average.
| GMED | MCD | |
|---|---|---|
Market Cap | $10.25B | $166.87B |
Volume | 1,108,124 | 4,543,119 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $341.06 |
52-Week Low | $58.33 | $230.88 |
Typical Hold Time | 0 Days | 165 Days |
Enterprise Value | $9.76B | $220.64B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
McDonald's (MCD) trades at $235.65, up 0.18% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 EPS of $3.38, beating expectations, and maintains robust profitability with a 31.72% net income margin. Recent news highlights McDonald's new 'NEXT' growth strategy focusing on automation and menu innovation to win back customers amid competitive pressures.
The stock offers a compelling long-term opportunity with 58.7% analyst buy ratings and a $284.70 consensus price target, representing 21% upside. Key risks include inflationary pressures on franchisee margins and high debt levels. The current valuation at 19.16x P/E appears reasonable given the company's stable cash flows and dividend consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
